Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAGLA | Q9Y4D2 | 4/20 | 0.40 |
| ▸ | PPARG | P37231 | 2/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | DAGLB | Q8NCG7 | 2/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | ADRB3 | P13945 | 5/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | TRPM8 | Q7Z2W7 | 3/20 | 0.37 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4575837 | 0.91 | PPARA (0.41) | PPARGADRB3 | |
| SCHEMBL4575158 | 0.89 | PPARD (0.38) | PPARGALOX5CYP2C9 | |
| SCHEMBL4574774 | 0.88 | PTGDR2 (0.41) | PPARGALOX5CYP2C9TRPM8 | |
| SCHEMBL4574795 | 0.88 | PPARG (0.38) | DAGLAPPARGALOX5CYP2C9TRPM8 | |
| SCHEMBL4575101 | 0.85 | FFAR1 (0.41) | DAGLAPPARGTRPM8 | |
| SCHEMBL4575828 | 0.85 | PPARA (0.47) | PPARG | |
| SCHEMBL4575060 | 0.84 | BCHE (0.43) | TRPM8 | |
| SCHEMBL4576198 | 0.81 | PPARA (0.44) | PPARG | |
| SCHEMBL4575576 | 0.80 | PPARA (0.50) | PPARG | |
| SCHEMBL4575105 | 0.79 | PPARA (0.52) | PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7319104-B2 | hPPARs activators | SMITHKLINE BEECHAM CORPORATION (US) | 2008-01-15 | — | — | US | disclosed |
| US-7319104-B2 | hPPARs activators | SMITHKLINE BEECHAM CORPORATION (US) | 2008-01-15 | — | — | US | disclosed |
| US-7319104-B2 | hPPARs activators | SMITHKLINE BEECHAM CORPORATION (US) | 2008-01-15 | — | — | US | disclosed |
| US-20050137212-A1 | Hppars activators | SMITHKLINE BEECHAM CORPORATION | 2005-06-23 | — | — | US | disclosed |
| EP-1480957-A1 | HPPARS ACTIVATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-12-01 | — | — | EP | disclosed |
| WO-2003074495-A1 | HPPARS ACTIVATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137212-A1 | Hppars activators | PPARG, PPARA, PPARD | DAGLA 235/4885PPARG 1/4885ALOX5 744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.